OncoSec Medical Incorporated (ONCS)

Business: OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer.

IPO Date: 31-Mar-2011

VP of Fin. and Principal Accounting Officer & Controller: Mr. Robert J. DelAversano CPA

Pres & CEO: Dr. Robert H. Arch Ph.D.

Listing: NASDAQ: ONCS

Country: United States

Headquarters: Pennington, NJ

Website: https://oncosec.com

Market cap: $30.97 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-37.76 Mln

Cash: $19.48 Mln

Total Debt: $5.49 Mln

Insider's Holding: 56.11%

Liquidity: Low

52 Week range: $0.67 - 4.25

Shares outstanding: 39,365,500

10 Years Aggregate:

• CFO: $-198.70 Mln
• EBITDA: $-245.96 Mln
• Net Profit: $-247.94 Mln